16:30 – 17:50
SESIÓN 3:
General Topic 2
| Chair: | Carlos Barrios, Latin American Cooperative Oncology Group, Porto Alegre, Brazil |
| 16:30 - 16:50 | ctDNA monitoring of residual disease to guide adjuvant therapy in early breast cancer Isaac García Murillas, The Institute of Cancer Research, London, UK |
| 16:50 - 17:10 | Guiding therapy with blood based biomarkers in advanced breast cancer Angel Guerrero, Instituto Valenciano de Oncología, Spain |
| 17:10 - 17:30 | Immune-mediated resistance to CDK4/6 inhibitors Giulia Petroni, Department of Experimental and Clinical Medicine, University of Florence, Italy |
| 17:30 - 17:50 | Discussion |
| 17:50 - 18:00 | Break |
18:00 – 19:20
SESIÓN 4:
Therapy 2
| Chair: | Sara López Tarruella, Hospital General Universitario Gregorio Marañon, Madrid, Spain |
| 18:00 - 18:20 | Therapeutic approach after resistance to CDK4/6 inhibition Miguel Martin, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, Spain |
| 18:20 - 18:40 | Antibody-drug conjugates for triple negative advanced breast cancer Sara M Tolaney, Dana Farber Cancer Institute, Boston, USA |
| 18:40 - 19:00 | Maintenance strategies in HER2-positive advanced breast cancer Veronique Dieras, Centre Eugène Marquis, Rennes, France |
| 19:00 - 19:20 | Discussion |
| 19:20 - 19:30 | CLOSING REMARKS |